Narcan (naloxone) is Emergent Biosolutions's drug known for treating opioid overdose and has the formula: This drug has been in ANDA litigation with Teva, which received FDA approval in 2019 and invalidated Emergent's Orange Book-listed patents in the district court; that decision is on appeal to the Federal Circuit. Emergent reached a settlement agreement with Perrigo that licenses the company to bring its generic Narcan to market in 2033 or earlier should Emergent be unable to obtain reversal of the district court's decision invalidating its patents. Brovana (arformoterol) is Sunovion's drug for treating chronic obstructive pulmonary disease (COPD). It is a long-acting β 2 adrenoceptor agonist having the formula: All Sunovion's patents protecting this drug will expire in 2021, and several generic companies have received tentative FDA approval.